SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla moves up on receiving A1+ rating for short-term debt programme from India Ratings

30 Apr 2013 Evaluate

Cipla is currently trading at Rs. 408.15, up by 0.60 points or 0.15% from its previous closing of Rs. 407.55 on the BSE.

The scrip opened at Rs. 409.20 and has touched a high and low of Rs. 412.00 and Rs. 405.00 respectively. So far 48737 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 435.00 on 09-Jan-2013 and a 52 week low of Rs. 300.70 on 12-Jun-2012.

Last one week high and low of the scrip stood at Rs. 413.55 and Rs. 392.25 respectively. The current market cap of the company is Rs. 32646.78 crore.

The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.08% and 28.32% respectively.

Credit rating agency, India Ratings & Research has assigned A1+ rating to Cipla’s Rs 1,000 crore commercial paper/ short-term debt programme.

The rating reflects the company’s comfortable credit profile with financial leverage (adjusted debt net of cash/EBITDAR) below 1.5x over FY09-FY12 (year end March). The low level of financial leverage provides the company enough headroom to take on additional debt.

Cipla focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×